Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/7/2019
SIETES contiene 92793 citas

 
 
<< anterior 21 a 40 de 518 siguiente >>
Presentar resultados
Seleccionar todas
22. Cita con resumen
23. Cita con resumen
Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol 2016:14 de abril. [Ref.ID 100161]
24.Enlace a cita originalTiene citas relacionadas Cita con resumen
Schoenfeld AJ, Grady D. Adverse effects associated with proton pump inhibitors. JAMA Intern Med 2016;176:febrero. [Ref.ID 99958]
25.Tiene citas relacionadas Cita con resumen
Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, Grams ME. Proton pump inhibitor use and risk of chronic kidney disease. JAMA Intern Med 2016;176:febrero. [Ref.ID 99957]
26.Tiene citas relacionadas
Drazen JM, Morrissey S, Campion EW, Jarcho JA. A SPRINT to the finish. N Engl J Med 2015;373:2174-5. [Ref.ID 99776]
28. Cita con resumen
Anónimo. Drugs past their expiration date. Med Lett Drugs Ther 2015;57:164-5. [Ref.ID 99690]
29.Tiene citas relacionadas Cita con resumen
The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2013-6. [Ref.ID 99661]
30.Tiene citas relacionadas Cita con resumen
Malhi GS. Lithium therapy in bipolar disorder: a balancing act?. Lancet 2015;386:415-6. [Ref.ID 99396]
31. Cita con resumen
Trecki J, Gerona RR, Schwartz MD. Synthetic cannabinoid - Related illnesses and deahts. N Engl J Med 2015;373:103-7. [Ref.ID 99338]
32.Enlace a cita original Cita con resumen
Caldeira D, Gonçalves N, Pinto FJ, Costa J, Ferreira J. Risk of renal failure with the non-vitamin K antagonist oral anticoagulants: systematic review and meta-analysis. Pharmacoepidemiol Drug Saf 2015;24:757-64. [Ref.ID 99318]
33.Tiene citas relacionadas Cita con resumen
Shine B, McKnight RF, Leaver L, Geddes JR. Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data. Lancet 2015;386:461-8. [Ref.ID 99217]
34. Cita con resumen
Kumar B, Swee ML. Nonsteroidal anti-inflammatory drug use in a patient with hypertension: a teachable moment. JAMA Intern Med 2015;175:892-3. [Ref.ID 99182]
35. Cita con resumen
Krishna VN, Warnock DG, Saxena N, Rizk DV. Oral anticoagulants and risk of nephropathy. Drug Saf 2015;38:527-33. [Ref.ID 99169]
36. Cita con resumen
Warlé-van Herwaarden MF, Valkhoff VE, Herings RMC, Engelkes M, van Blijderveen JC, Rodenburg EM, de Bie S, Alsma J, van de Steeg-Gompel C, Kramers C, Meyboom RHB, Sturkenboom MCJM, De Smet PAGM. Quick assessment of drug-related admissions over time (QUADRAT study). Pharmacoepidemiol Drug Saf 2015;24:495-503. [Ref.ID 98885]
37. Cita con resumen
Li DQ, Kim R, McArthur E, Fleet JL, Bailey DG, Juurlink D, Shariff SZ, Gomes T, Mamdani M, Gandhi S, Dixon S, Garg AX. Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. Can Med Assoc J 2015;187:174-80. [Ref.ID 98758]
38.Enlace a cita originalTiene citas relacionadas Cita con resumen
Jessup M, Komajda FM, McMurray JJV, Packer M. Perspective roundtable: PARADIGM-HF - The experts' discussion. N Engl J Med 2014;371:e15. [Ref.ID 98475]
39. Cita con resumen
Anónimo. FDA approves weight-management drug Saxenda. U.S. Food and Drug Administration 2014:23 de diciembre. [Ref.ID 98393]
40.Tiene citas relacionadas Cita con resumen
Poeran J, Rasul R, Suzuki S, Danninger T, Mazumdar M, Opperer M, Boettner F, Memtsoudis SG. Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety. BMJ 2014;349:g4829. [Ref.ID 98189]
Seleccionar todas
 
<< anterior 21 a 40 de 518 siguiente >>